Hanmi Pharmaceutical said in a regulatory filing on Wednesday that its consolidated operating profit last year rose 19.2% from a year earlier to 257.8 billion won, based on preliminary results. Revenue increased 3.5% to 1.5475 trillion won, and net profit climbed 33.9% to 188.1 billion won.
The company said the results were driven by steady growth in key products including Rosuzet, higher income from supplying clinical trial samples and technology fees from partner MSD, and progress in normalizing operations at Beijing Hanmi.
In the fourth quarter of 2025, revenue rose 23.1% from a year earlier to 433.0 billion won, while operating profit jumped 173.4% to 83.3 billion won.
Hanmi Pharmaceutical said it generated 1.0836 trillion won in sales from outpatient prescriptions alone, marking its eighth straight year as the top seller in South Korea’s outpatient prescription market. Rosuzet, a combination drug for dyslipidemia, posted prescription sales of 227.9 billion won, up 8.4% from a year earlier. The Amodartan Family line of combination hypertension drugs recorded 145.4 billion won in sales last year.
Its China unit, Beijing Hanmi Pharmaceutical, supported the performance as annual revenue topped 400.0 billion won last year, the first time since its founding that it has exceeded that level.
Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients, posted 91.3 billion won in revenue last year. Fourth-quarter revenue rose 36.8% from a year earlier to 28.3 billion won. The company said fourth-quarter operating profit returned to the black on new contract development and manufacturing orders and expanded volumes for existing projects.
Hanmi Pharmaceutical said it plans to launch at least one “flagship product” a year worth more than 10.0 billion won in annual sales, starting with Amoprel, billed as the world’s first one-third low-dose antihypertensive drug introduced in the second half of last year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.